Sonnet BioTherapeutics Holdings, Inc. (SONN)
Stock Price:
$2.61 USD
-0.07 (-2.61%)
Updated Sep 22, 2020 11:18 AM EDT - Market closed
Key Info
| Market Cap |
35.61M |
| Revenue (ttm) |
14.92M |
| Net Income (ttm) |
-26.34M |
| Shares Out |
13.64M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 22, 2020 |
| Last Price |
$2.61 |
| Previous Close |
$2.68 |
| Change ($) |
-0.07 |
| Change (%) |
-2.61% |
| Day's Open |
2.62 |
| Day's Range |
2.55 - 2.66 |
| Day's Volume |
526,461 |
| 52-Week Range |
2.32 - 54.60 |
More Stats
| Market Cap |
35.61M |
| Enterprise Value |
32.88M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.64M |
| Float |
11.78M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
556,272 |
| Short Ratio |
0.09 |
| Short % of Float |
0.00% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.39 |
| PB Ratio |
93.76 |
| Revenue |
14.92M |
| Operating Income |
-24.51M |
| Net Income |
-26.34M |
| Free Cash Flow |
-12.80M |
| Net Cash |
2.73M |
| Net Cash / Share |
0.20 |
| Gross Margin |
n/a |
| Operating Margin |
-164.30% |
| Profit Margin |
-177.10% |
| FCF Margin |
-85.82% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-233.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
8.00
Current: $2.61
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 30.14 | 30.73 | 41.43 | 41.70 | 35.35 | 29.84 | 8.25 | 6.85 | 1.48 | 0.14 |
| Revenue Growth | -1.92% | -25.82% | -0.65% | 17.96% | 18.46% | 261.85% | 20.36% | 364.05% | 983.37% | - |
| Gross Profit | 1.24 | 2.61 | 4.31 | 5.67 | 3.92 | 2.55 | 0.31 | 0.31 | 0.37 | 0.14 |
| Operating Income | -16.08 | -5.37 | -5.24 | -2.62 | -5.08 | -5.54 | -4.61 | -2.59 | -0.96 | -1.06 |
| Net Income | -17.73 | -6.85 | -6.79 | -9.08 | -12.14 | -6.40 | -5.21 | -3.17 | -1.16 | -1.01 |
| Shares Outstanding | 0.27 | 0.14 | 0.10 | 0.08 | 0.05 | 0.02 | 0.02 | 0.01 | - | - |
| Earnings Per Share | -66.56 | -51.48 | -70.98 | -108.68 | -221.01 | -265.21 | -312.01 | -325.01 | -254.81 | -265.21 |
| Operating Cash Flow | -4.05 | -1.11 | -0.72 | -0.51 | -5.25 | -1.03 | -2.70 | -2.38 | -1.16 | -0.76 |
| Capital Expenditures | -0.47 | -1.70 | -1.16 | -1.18 | -1.80 | -1.97 | -3.66 | -1.17 | -0.22 | - |
| Free Cash Flow | -4.52 | -2.81 | -1.89 | -1.69 | -7.05 | -3.00 | -6.36 | -3.55 | -1.38 | -0.76 |
| Cash & Equivalents | 0.50 | 0.52 | 0.44 | 0.27 | 1.22 | 0.25 | 0.44 | 1.22 | 0.17 | 0.05 |
| Total Debt | 24.31 | 9.66 | 8.95 | 10.16 | 9.35 | 8.82 | 1.82 | 0.32 | 3.16 | 0.94 |
| Net Cash / Debt | -23.81 | -9.14 | -8.52 | -9.89 | -8.12 | -8.57 | -1.37 | 0.90 | -3.00 | -0.89 |
| Assets | 31.53 | 29.79 | 30.18 | 33.49 | 42.21 | 35.79 | 20.09 | 7.65 | 4.80 | 1.41 |
| Liabilities | 34.68 | 21.54 | 18.69 | 19.78 | 20.45 | 20.82 | 8.85 | 2.12 | 4.31 | 1.33 |
| Book Value | -3.61 | 7.43 | 10.71 | 12.56 | 21.37 | 10.07 | 10.84 | 5.46 | -0.11 | 0.06 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sonnet BioTherapeutics Holdings, Inc. |
| Country |
United States |
| Employees |
30 |
| CEO |
Pankaj Mohan |
Stock Information
| Ticker Symbol |
SONN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SONN |
Description
SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.